Correction of placental dysfunction in the first trimester of pregnancy as a method of preventing fetal growth retardation

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.67.102-106

Keywords:

placental dysfunction, prevention, fetal growth retardation

Abstract

Objective: to study the effectiveness of complex therapy of placental dysfunction (PD) as a method of prevention of fetal growth retardation syndrome in pregnant women with miscarriage in the 1st trimester of pregnancy.
Materials and methods. 100 pregnant women with verified PD on the background of miscarriage in the first trimester of pregnancy took part in the study.
Verification criteria for PD were: a decrease in the volume of the chorion and its vascularization index by more than 15%, an increase of the resistance index in the uterine and spiral arteries during dopplerometric examination at the end of the first trimester of pregnancy.
The patients were divided into groups: group I (main) – 36 pregnant women with PD who received complex treatment, group II (comparative) – 32 pregnant women with PD who were prescribed only hormonal support, III group (control) – 32 patients with the physiological course of the first trimester of pregnancy. Complex therapy in the group I included hormonal agents, venotonic drug Normoven, the drug Magnicum, and the drug Artihol.
Clinical data, ultrasound fetometry, dopplerometric study of utero-fetal blood flow were used to assess the effectiveness of treatment.
Results. Already in the 22–24th week of gestation there was no significant difference in the resistance index in the spiral and uterine arteries between the main and control groups (p > 0.05). Ultrasound fetometry at 32–34 weeks of gestation showed that in the first group there were 8.3% (3) fetuses small for gestational age, 15.6% (5) in the second group and 3.1% (1) in the control. The average body weight of newborns in the main group and in the comparison group differed significantly and was 2810 ± 267 and 2610 ± 175 g respectively (р < 0.05) and 3295 ± 295 g in the control group.
Conclusions. Complex, pathogenetically justified, long-term treatment of PD from the early stages of pregnancy makes it possible to avoid progression of compensated and development of subcompensated stages of placental disorders. Complex therapy of PD, which includes micronized progesterone, Normoven, Artichol and Magnicum, Complex PD therapy, which includes micronized progesterone, Normoven, Artihol and Magnicum, normalizes blood flow in the mother-placenta-fetus system, normal growth and fetus development and is an effective way of preventing fetal growth retardation.

Author Biography

О.V. Kravchenko, Higher State Educational Institution of Ukraine “Bukovinian State Medical University”, Chernivtsi

MD, professor, head of Obstetrics, Gynecology and Perinatology Department

References

  1. Boyko, V.I., Butenko, O.I. “Fetal development delay in premature pregnancy: diagnosis and prevention of perinatal pathology.” Health of women (2017): 124–6. DOI: 10.15574/HW.2017.117.124
  2. Vdovichenko, Y.P., Golyanovsky, V.O. “Determination of diagnostic markers of fetal growth retardation in early pregnancy.” Reproductive health of women 1.46 (2021): 61–5. DOI: 10.30841/2708-8731.1.2021.229717
  3. Vdovichenko, Y.P., Tanko, O.P., Samoilova, M.V., Sharashidze, K.Z. Fetal growth retardation: clinical and pathogenetic components and means of prevention. Adaptation to international clinical institutions. Kyiv (2017): 44.
  4. Veropotvelyan, N.P., Veropotvelyan, P.N., Zhuravleva, S.A., Glamazda, A.I. “Intrauterine growth retardation, mental and physical development of children.” Women’s health 3 (2016): 141–8. DOI: 10.15574/HW.2016.109.141
  5. Gromova, A.M., Berezhna, V.A. “Etiological and pathogenetic aspects of intrauterine fetal development delay.” Actual problems of modern medicine: Bulletin of the Ukrainian Medical Stomatological Academy 18.3.63 (2018): 301–7.
  6. Kyrylchuk, M.E., Islamova, O.V. “Miscarriage and magnesium. What is known.” Female doctor 1.93 (2021): 20–5.
  7. Loskutova, T.O. “Polymorphism of the genes of the hemostasis system, endothelial dysfunction and blood pressure regulation in pregnant women with preeclampsia and fetal growth retardation.” Pathology 15.1 (2018): 29–33. DOI: 10.14739/2310-1237.2018.1.127709
  8. Markin L.B., Matvienko, O.O. “Peculiarities of ultrasound diagnostics in fetal growth retardation syndrome (FGR).” Health of women 9.135 (2018): 19–20. DOI: 10.15574/HW.2018.135.19
  9. Sukhanova, A.A., Savchenko, S.E., Karlova, O.O., Onishchik, L.M. “New opportunities in complex therapy of placental dysfunction.” Female doctor 2.88 (2020): 30–5.
  10. Khlibovska, O.I., Ovcharuk, V.V., Jivak, V.G. “The course of pregnancy and childbirth in women with fetal growth retardation.” Current issues of pediatrics, obstetrics and gynecology 1 (2014): 168–70.
  11. Shcherbina, H.A., Makarenko, M.V. “Clinical and morphological aspects of the development of fetal growth retardation syndrome.” Experimental and clinical medicine 3.64 (2014): 143–7.
  12. Álvarez-Nava, F., Lanes, R. “GH/igf-1 signaling and current knowledge of epigenetics; a review and considerations on possible therapeutic options.” Int J Mol Sci 18.10 (2017): 1–13. DOI: 10.3390/ijms18101624
  13. Easter, S.R., Eckert, L.O., Boghossian, N., et al. “Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.” Vaccine 35.48 (2017): 6546–54. DOI: 10.1016/j.vaccine.2017.01.042
  14. Eggermann, T., Oehl-Jaschkowitz, B., Dicks, S., et al. “The maternal uniparental disomy of chromosome 6 (upd(6)mat) “phenotype”: result of placental trisomy 6 mosaicism?” Mol Genet Genomic Med 5.6 (2017): 668–77. DOI: 10.1002/mgg3.324
  15. Groom, K.M., Mc Cowan, L.M., Mackay, L.K., et al. “Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial.” Am J Obstet Gynecol 216.3 (2017): 296.e1-296.e14. DOI: 10.1016/j.ajog.2017.01.014
  16. Kanat-Pektas, M., Yesildager, U., Tuncer, N., et al. “Could mean platelet volume in late first trimester of pregnancy predict intrauterine growth restriction and pre-eclampsia?” Obstet Gynaecol Res 40.7 (2014): 1840–5. DOI: 10.1111/jog.12433
  17. Kehl, S., Dötsch, J., Hecher, K., et al. “Intrauterine Growth Restriction. Guideline of the German Society of Gynecology and Obstetrics.” Geburtshilfe Frauenheilkd 77.11 (2017): 1157–73. DOI: 10.1055/s-0043-118908
  18. Levine, T.A., Grunau, R.E., McAuliffe, F.M., et al. “Early childhood neurodevelopment after intrauterine growth restriction: a systematic review.” Pediatrics 135.1 (2015): 126–41. DOI: 10.1542/peds.2014-1143
  19. Radoń-Pokracka, M., Huras, H. “Intrauterine growth restriction diagnosis and treatment.” Przegl Lek 72.7 (2015): 376–82.
  20. Reddy, U.M., Davis, J.M., Ren, Z., Greene, M.F. “Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes.” Obstet Gynecol 130.1 (2017): 10–28. DOI: 10.1097/AOG.0000000000002054
  21. Shapouri-Moghaddam, A., Mohammadian, S., Vazini, H., et al. “Macrophage plasticity, polarization, and function in healthand disease.” J Cell Physiol 233.9 (2018): 6425–40. DOI: 10.1002/jcp.26429
  22. Devaskar, S.U., Chu, A. “Intrauterine Growth Restriction: Hungry for an Answer.” American Physiological Society 31.2 (2016): 131–46. DOI: 10.1152/physiol.00033.2015
  23. Sibley, C.P. “Treating the dysfunctional placenta.” J Endocrinol 234.2 (2017): R81-R97. DOI: 10.1530/JOE-17-0185
  24. Stirnemann, J., Villar, J., Salomon, L.J., et al. “International estimated fetal weight standards of the intergrowth-21st project.” Ultrasound Obstet Gynecol 49.4 (2017): 478–86. DOI: 10.1002/uog.17347
  25. Ureyen, I., Ozyuncu, O., Sahin-Uysal, N., et al. “Relationship of maternal mean platelet volume with fetal Doppler parameters and neonatal complications in pregnancies with and without intrauterine growth restriction.” Matern Fetal Neonatal Med 30.4 (2017): 471–4. DOI: 10.1080/14767058.2016.1175423
  26. Winterhager, E., Gellhaus, A. “Transplacental nutrient transport mechanisms of intrauterine growth restriction in rodent models and humans.” Front Physiol 8 (2017): 1–13. DOI: 10.3389/fphys.2017.00951

Downloads

Published

2023-03-31

How to Cite

Kravchenko О. (2023). Correction of placental dysfunction in the first trimester of pregnancy as a method of preventing fetal growth retardation. REPRODUCTIVE ENDOCRINOLOGY, (67), 102–106. https://doi.org/10.18370/2309-4117.2023.67.102-106

Issue

No. 67 (2023)

Section

Pregnancy and childbirth

License

Copyright (c) 2023 О.В. Кравченко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.